There remain unmet clinical needs in platinum-resistant advanced small cell lung cancer (SCLC) with a low ORR of approximately 20% and a PFS of about 4 months. Recently, DLL3 has emerged as a specific biomarker for SCLC. Guo and colleagues conjugated a topoisomerase I inhibitor to a DLL3 antibody with Fc silencing mutations via a novel Val-Ala linker to form an innovative ADC, FZ-AD005. FZ-AD005 exhibited strong anti-tumor activity in multiple tumor models. FZ-AD005 was stable and well tolerated in cynomolgus monkeys, with no ILD observed during repeated administration. Taken together, these results indicate that FZ-AD005 is a promising therapeutic to improve the treatment of advanced SCLC.

While there are approved targeted therapies for patients with KRAS G12C and EGFR mutations in non-small cell lung cancer, novel therapies that target additional genomically-defined patient populations, such as NF1, as well as rational combination strategies that augment responses to available therapies,...

You do not currently have access to this content.